Low Nephron Number and Its Clinical Consequences

by Valerie A. Luyckx, Khuloud Shukha, Barry M. Brenner
Published 2011-10-01

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

by Hans-Henrik Parving, Barry M Brenner, John JV McMurray, Dick de Zeeuw, Steven M Haffner, Scott D Solomon, Nish Chaturvedi, Frederik Persson, Maria Nicolaides, Alexia Richard, Zhihua Xiang, Juergen Armbrecht, Marc A Pfeffer
Published 2012-09-01

The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

by Barry M Brenner, Mark E Cooper, Dick de Zeeuw, Jean-Pierre Grunfeld, William F Keane, Kiyoshi Kurokawa, Janet B McGill, William E Mitch, Hans Henrik Parving, Guiseppe Remuzzi, Arthur B Ribeiro, Mark D Schluchter, Duane Snavely, Zhongxin Zhang, Roger Simpson, Denise Ramjit, Shahnaz Shahinfar, RENAAL Study Investigators
Published 2000-12-01